What are the top holdings of Tata India Pharma & Healthcare Fund Direct-Growth?
The top holdings of Tata India Pharma & Healthcare Fund Direct-Growth as of 30 Sep 2026 are Sun Pharmaceutical Industries Ltd. (7.99%), Abbott India Ltd. (5.94%), Healthcare Global Enterprises Ltd. (5.92%), Divis Laboratories Ltd. (5.68%), Dr. Reddys Laboratories Ltd. (4.65%). These top 5 stocks together account for 30.18% of the total portfolio. You can view the complete holdings breakdown above.
How many stocks does Tata India Pharma & Healthcare Fund Direct-Growth hold in its portfolio?
Tata India Pharma & Healthcare Fund Direct-Growth holds 43 stocks in its portfolio as of 30 Sep 2026. The fund's portfolio size reflects the fund manager's investment approach, a more concentrated portfolio indicates higher conviction bets, while a larger number of holdings suggests a more diversified strategy.
What is the sector allocation of Tata India Pharma & Healthcare Fund Direct-Growth?
As of 30 Sep 2026, Tata India Pharma & Healthcare Fund Direct-Growth's top sector allocations are Healthcare (88.97%), Chemicals (9.52%), Consumer Staples (1.23%). You can find detailed sector allocation above.
What is the equity and debt allocation of Tata India Pharma & Healthcare Fund Direct-Growth?
As of 30 Sep 2026, Tata India Pharma & Healthcare Fund Direct-Growth has 99.72% allocated to equity, and 0.00% to debt. You can also check the historical trends above.
What is the market cap allocation of Tata India Pharma & Healthcare Fund Direct-Growth?
As of 30 Sep 2026, Tata India Pharma & Healthcare Fund Direct-Growth's market cap allocation is 26.08% in large caps, 34.56% in mid caps, and 39.36% in small caps.
What is the PE ratio of Tata India Pharma & Healthcare Fund Direct-Growth's portfolio?
The portfolio PE ratio of Tata India Pharma & Healthcare Fund Direct-Growth is 42.21 as of 30 Sep 2026. The portfolio PE ratio tells you how expensive or cheap the fund's holdings are relative to their earnings.
What is the credit quality of Tata India Pharma & Healthcare Fund Direct-Growth?
A credit rating breakdown is not available for Tata India Pharma & Healthcare Fund Direct-Growth β its non-equity allocation was 0.00% as of the latest disclosure. This is common when a fund's non-equity holdings are mostly cash or short-term money market instruments, which aren't assigned a credit rating the way bonds are.
When is the latest portfolio disclosure for Tata India Pharma & Healthcare Fund Direct-Growth?
The latest portfolio disclosure for Tata India Pharma & Healthcare Fund Direct-Growth is as of 30 Sep 2026. SEBI requires all mutual funds to disclose their complete portfolio holdings on a monthly basis, typically within 10 days of the end of each month.